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Abstract  
Objective After implantation of drug-eluting stents (DES), patients usually receive 
6-12 months of dual antiplatelet therapy (DAPT). However, the optimal duration of 
DAPT is controversial. Therefore, we performed a meta-analysis of randomized 
controlled trials to assess the risks and benefits of different DAPT durations.  
Methods We searched the literature using MEDLINE, Scopus, EMBASE, ISI Web of 
Science, Cochrane Library, ClinicalTrials.gov and recent conference proceedings, and 
included those trials randomizing patients to receive different durations of DAPT after 
DES implantation and reporting frequencies of cardiovascular and bleeding events. 
Data from eleven trials were analyzed using RevMan.  
Results Compared to 12-month DAPT treatment, extended DAPT significantly 
reduced the frequencies of myocardial infarction (OR 0.54 95%CI: 0.43-0.66; 
p<0.00001) and stent thrombosis (OR 0.36 95%CI: 0.24-0.55; p<0.00001), but the 
risks of major bleeding (OR 1.54 95%CI 1.22-1.96) and all-cause mortality (OR 1.43 
95%CI 1.14-1.81) were substantially increased. There was no significant difference in 
stroke, cardiovascular mortality or repeat revascularization. Compared to short-term 
DAPT, 12-month DAPT or longer was associated with increased major bleeds (OR 
1.98 95%CI: 1.26-3.11). No significant differences were found in the risk of other 
primary outcomes.  
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Conclusion 12-month DAPT appears to be a pragmatic compromise between 
preventing stent thrombosis and increasing bleeding risk. Patients at high bleeding 
risk should have shorter duration DAPT while those with low bleeding risk can be 
considered for DAPT beyond 12 months. 
Keywords Drug-eluting stent; Dual antiplatelet therapy; Bleeding; Meta-analysis 
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1 Introduction 
Drug-eluting stents (DES)5 have been widely used in percutaneous coronary intervention in 
combination with medical treatment for relieving angina. Although DES cause less restenosis 
than bare metal stents, delayed endothelial healing may increase the risk of late stent 
thrombosis. To prevent this, dual antiplatelet therapy (DAPT)6 is given for a certain period 
of time [1,2]. Current clinical guidelines recommend 6-12 months DAPT after DES 
implantation. However, they are largely based on observational data and small randomized 
controlled trials [3,4]. Recent trials with newer generation DES have suggested that 
short-term DAPT is safe, and can therefore replace 12 months’ therapy [5-11]. Whether 
extended duration of DAPT over 12 months is superior has also been questioned; inconsistent 
results were found in clinical trials comparing different durations of DAPT [12-16]. In 
general, short-term DAPT (<12 months) is associated with a lower frequency of major 
bleeding, but early discontinuation of DAPT could increase the risk of late stent thrombosis 
[17-19]. A recent large randomized controlled trial showed a significant reduction of 
myocardial infarction and stent thrombosis with extended DAPT [15]. However, the potential 
superiority of extended DAPT duration has been challenged recently [16]. The optimal 
5 DES, drug-eluting stents. 
6 DAPT, dual antiplatelet therapy. 
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duration of DAPT is controversial, and needs to be re-examined in the light of recent trial 
evidence to guide clinical practice. Therefore, we conducted a meta-analysis comparing 
either short-term DAPT or extended DAPT with 12 months’ therapy in patients receiving 
DES implantation, aiming to find out the efficacy and safety of different DAPT durations. 
2 Methods 
We searched the literature written in English on randomized trials comparing different DAPT 
durations after DES implantation up to 28 January 2016. MEDLINE, EMBASE, Scopus, ISI 
Web of Science, Cochrane Library, ClinicalTrials.gov, recent meta-analyses and cardiology 
conference abstracts were searched using the terms “dual antiplatelet therapy”, “DAPT”, 
“P2Y12”, “clopidogrel”, “drug-eluting stent”, “myocardial infarction”, “stent thrombosis”, 
and “bleeding”. The inclusion criteria for this meta-analysis were: (1) a randomized 
controlled trial of different durations of DAPT; (2) participants had to be over 18 years of age; 
(3) the trial had to report the incidence of cardiovascular and bleeding events; and (4) patients 
receiving percutaneous coronary intervention with DES. Two investigators conducted the 
literature assessment, risk of bias assessment and data extraction independently; divergences 
were resolved to reach a consensus. Selected trials were stratified according to the durations 
of DAPT into three groups: (1) >12 months DAPT vs. 12 months DAPT; (2) >12 months 
DAPT vs. <12 months DAPT; (3) <12 months DAPT vs. 12 months DAPT.  
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Primary outcomes were frequencies of myocardial infarction, definite/probable stent 
thrombosis and stroke. Secondary outcomes were frequencies of cardiovascular mortality, 
all-cause mortality, major bleeding and repeat revascularization. Statistical analysis was 
performed using RevMan version 5.3.4. Odds ratios (OR) and 95% confidence intervals (95% 
CI) were used as summary statistics; summary OR for categorical variables were calculated 
using random effects model. Heterogeneity among studies was assessed by I2 statistics. We 
also conducted sensitivity analysis to evaluate the effect of the inclusion or exclusion of trials. 
Potential publication bias and selection bias were examined using funnel plots, Begg’s, 
Egger’s and trim-and-fill tests. P < 0.05 was considered statistically significant. The reporting 
of meta-analysis was performed in compliance with the PRISMA Statement. The protocol for 
our meta-analysis has been registered on PROSPERO (http://www.crd.york.ac.uk/prospero, 
registration number: CRD42016037587). 
3 Results 
A summary of the screening and selection process is described in the PRISMA flowchart 
(Supplementary Fig.1). Eleven randomized controlled trials (n = 33520) were included in the 
meta-analysis. Their characteristics and results for risk of bias assessment are shown in Table 
1, Supplementary Tables S1 and S2.
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Table 1 Summary of design for studies included in meta-analysis 
Studies 
(ClinicalTrials.gov 
Identifier) 
Number of 
participants 
Treatment 
durations 
(months) 
Stent type DAPT drugs Primary endpoints 
Bleeding 
criteria 
RESET 2012 [9] 
(NCT01145079) 
2,117 12 vs. 3 
SESa, EESb, E-ZESb, 
R-ZESb 
Clopidorgrel + 
ASA 
Composite of cardiac death, MI, ST, 
ischemia-driven TVR or bleeding 
TIMI 
EXCELLENT 2012 [6] 
(NCT00698607) 
1,443 12 vs. 6 SESa, EESb 
Clopidorgrel + 
ASA 
Composite of cardiac death, MI or 
ischemia-driven TVR 
TIMI 
PRODIGY 2012 [5] 
(NCT00611286)  
1,970 24 vs. 6 
BMS, PESa, ZESb, 
EESb 
Clopidorgrel + 
ASA 
Death, MI or CVA TIMI 
OPTIMIZE 2013 [10] 
(NCT01113372) 
3,119 12 vs. 3 E-ZESb 
Clopidorgrel + 
ASA 
Death, MI, CVA or major bleeding 
REPLACE-2, 
GUSTO 
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DES-LATE 2014 [13] 
(NCT01186146) 
5,045 24 vs. 12c,d 
SESa, PESa; ZESb, 
EESb 
Clopidorgrel + 
ASA 
Composite of cardiac death, MI, stroke TIMI 
ARCTIC-Interruption 2014 
[14] (NCT00827411) 
1,259 18–30 vs. 12c DES 
Thienopyridine 
+ ASA 
Composite of death, MI, ST, stoke or 
urgent TVR 
STEEPLE 
OPTIDUAL 2014 [16] 
(NCT00822536) 
1,385 30 vs. 12 
SESa, PESa; ZESb, 
EESb 
Clopidorgrel + 
ASA 
Composite of death, MI, stoke or major 
bleeding 
ISTH 
SECURITY 2014 [8] 
(NCT00944333) 
1,399 12 vs. 6 DESb 
Clopidorgrel + 
ASA 
Composite of cardiac death, MI, stoke, 
ST, or bleeding 
BARC 
ITALIC 2014 [7] 
(NCT01476020) 
1,822 24 vs. 6e EESb 
Clopidorgrel, 
prasugrel or 
ticagrelor + 
ASA 
Composite of death, MI, stoke, urgent 
TVR, stroke or major bleeding 
TIMI 
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ISAR-SAFE 2014 [11] 
(NCT00661206) 
4,000 12 vs. 6 
BES, SESa, EESb, 
ZESb 
Clopidogrel + 
antiplatelet 
drug (not 
specified)  
Composite of Death, MI, ST, stoke or 
major bleeding 
TIMI 
DAPT 2014 [15] 
(NCT00977938) 
9,961 30 vs. 12 
SESa, PESa; ZESb, 
EESb; BMSf 
Thienopyridine 
+ ASA 
Composite of death, MI, stroke, ST or 
bleeding 
BARC, 
GUSTO 
Abbreviations used in this table: ASA = aspirin; ST = stent thrombosis; MI = myocardial infraction; CVA = cerebrovascular accident; TVR = target vessel 
revascularization; DES = drug-eluting stent; BES = biolimus-eluting stent; BMS = bare metal stent; EES = everolimus-eluting stent; ZES = zotarolimus-eluting stent; 
PES = paclitaxel-eluting stent; SES = sirolimus-eluting stent; E-ZES = endeavor zotarolimus-eluting stent; R-ZES = resolute zotarolimus-eluting stent, DAPT = dual 
antiplatelet therapy. 
a First-generation DES: PES SES; 
b Second-generation DES: ZES EES. 
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c Patients in ARCTIC-Interruption and DES-LATE study had previous DAPT.  
d DES-LATE study allowed patient enrolment with 1 year or longer after percutaneous coronary intervention.  
e First year data of ITALIC study has been published. In the extended DAPT arm, 5.4% patients discontinued treatment before 24 months. 
f DAPT study allowed enrolment of patients with BMS but they were not included in statistical analysis. 
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Four studies comparing extended DAPT (>12 months) versus 12 months’ regimen and seven 
studies comparing short-term DAPT (<12 months) versus 12 months’ regimen were included. 
Clopidogrel and aspirin was the most frequent drug combination in dual antiplatelet therapy. 
Compared to 12-month DAPT, extended DAPT beyond 12 months [13-16] yielded a very 
significant reduction in the frequencies of myocardial infarction (OR 0.54 95% CI: 0.43-0.66; 
p < 0.00001) (Fig. 1A) and definite/probable stent thrombosis (OR 0.36 95% CI: 0.24-0.55; p 
< 0.00001) (Fig. 2A). There was no significant difference in the risk of cardiovascular 
mortality (OR 1.03 95% CI: 0.75-1.40) (Supplementary Fig. S2A), stroke (OR 0.93 95% CI: 
0.67-1.29) (Supplementary Fig. S3A) or repeat revascularization (OR 1.13 95% CI: 0.87-1.47) 
(Supplementary Fig. S4A). However, a significant increase in the risk of all-cause mortality 
(OR 1.43 95% CI 1.14-1.81, p = 0.002) (Fig. 3A) and major bleeding (OR 1.54 95% CI: 1.22 
to 1.96, p = 0.0004) (Fig. 4A) was also observed. 
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 Compared to short-term DAPT, 12 months’ regimen [6-11] and extended DAPT [5] showed 
no significant alteration in the risk of myocardial infarction (OR 0.88 95% CI: 0.69-1.13) 
(Fig. 1B), definite or probable stent thrombosis (OR 0.78 95% CI: 0.51-1.21) (Fig. 2B), 
cardiovascular mortality (OR 0.98 95% CI: 0.72-1.35) (Supplementary Fig. S2B) stroke (OR 
1.16 95% CI: 0.77-1.76) (Supplementary Fig. S3B), all-cause mortality (OR: 1.08; 95% CI: 
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0.85-1.36) (Fig. 3B), or repeat revascularization (OR 0.87 95% CI: 0.71-1.07) 
(Supplementary Fig. S4B), but the risk of major bleeding was significantly increased (OR 
1.98 95% CI: 1.26-3.11, p = 0.003) (Fig. 4B).  
No significant heterogeneity across the trials was found in the effect on stroke or repeat 
revascularization in all groups (I2 = 0). In trials comparing short-term and ≥12 months DAPT, 
no significant heterogeneity was found in the effect on myocardial infarction, stent 
thrombosis, cardiovascular mortality, all-cause mortality, and major bleeding. In the trials 
comparing extended DAPT and 12-month DAPT, insignificant heterogeneity was found in 
the effect on myocardial infarction, cardiovascular mortality and major bleeding (I2 = 13%, 
17%, 15%; p = 0.33, 0.30, 0.32, respectively). Significant heterogeneity was found in the 
effect on stent thrombosis and all-cause mortality across the trials comparing extended DAPT 
versus 12-month DAPT (I2 = 49% and 65% respectively). Therefore, sensitivity analysis 
comparing extended and 12-month DAPT was performed in both outcomes. OR and I2 of 
sensitivity analysis showing the effect of including and excluding each trial are summarized 
in Supplementary Tables S3 and S4. The heterogeneity in the risk of all-cause mortality was 
due to the OPTIDUAL trial. I2 could be reduced to 5% with a non-significant OR after 
excluding it. The heterogeneity in the risk of stent thrombosis was due to the DAPT and 
OPTIDUAL trials. Excluding either one of the studies resulted in a non-significant OR; 
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excluding the DAPT trial reduced I2 to 28% while excluding the OPTIDUAL trial reduced I2 
to 18%. No significant publication bias or small study effects were suggested by the funnel 
plots (Supplementary Figs S5A–S11B, Supplementary Table S5). 
4 Discussion 
The present meta-analysis comparing the efficacy and safety of three different durations of 
DAPT in patients receiving DES implantation shows two main findings: (1) compared to 
12-month DAPT, extended regimen reduced the incidence of myocardial infarction and 
definite/probable stent thrombosis, but at the price of more major bleeding as well as 
all-cause mortality, driven by non-cardiovascular deaths; (2) compared to 12-month DAPT, 
short-term therapy showed no significant difference in the frequency of stent thrombosis or 
myocardial infarction, but a reduction in the risk of major bleeding.  
Short-term DAPT definitely reduces the number of major bleeds, and appears to have similar 
efficacy to 12-month regimen, especially with new-generation DES and modern 
interventional techniques. Our finding is consistent with previous meta-analyses comparing 
short-term and extended DAPT, confirming the non-inferiority of short-term regimen [20-23]. 
Previous registry studies and some trials had suggested the benefits of extended DAPT, but 
they were criticized for being underpowered due to the bias from observational data or 
relatively small sample size [24-26]. The DAPT trial [15] was the largest randomized 
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controlled trial comparing the efficacy and safety of extended versus 12-month DAPT. The 
decrease in myocardial infarction and stent thrombosis with extended DAPT was further 
confirmed in this trial. However, extended DAPT was not favored in previous meta-analyses 
without DAPT study, which showed no apparent ischemic benefits and no significant 
increase in all-cause mortality with extended DAPT, but a significant increase in the 
frequency of major bleeding [20-23].  
As the most recent OPTIDUAL trial showed no significant difference in primary outcomes 
between 12 months’ therapy and extended DAPT [16], it was of great interest to see if a 
meta-analysis would settle the issue of the optimal duration of DAPT and guide clinical 
decision. Our meta-analysis included both the DAPT trial and OPTIDUAL trial, and yielded 
new conclusions, in that extended DAPT showed extremely significant protection against 
myocardial infarction and stent thrombosis (p < 0.00001), but with a concurrent increase in 
major bleeding and all-cause, although not cardiovascular, mortality. The excess death was 
possibly driven by non-cardiovascular events including bleeding. Recent meta-analyses that 
included the DAPT trial also showed this trend [27-29]. For every stent thrombosis being 
prevented, about one major bleeds will occur [27,29]. This highlights the importance of 
balancing the risks and benefits in the individual patient before making any treatment 
decision. No decrease was found in the incidence of repeat revascularization. The reason 
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might be that it was not an endpoint in DAPT, the largest trial, so there was not enough 
statistical power for this outcome.  
Our meta-analysis and other recent meta-analyses [27-29] have provided evidence that 
extended DAPT can significantly lower the incidence of myocardial infarction and stent 
thrombosis. There is no effective alternative to DAPT for preventing stent thrombosis after 
DES implantation, but there are ways of reducing bleeding risk, such as risk stratification, 
blood pressure control and prophylaxis with proton pump inhibitor. Therefore, extended 
DAPT could be considered for selected patients with low bleeding risk or those who tolerate 
it without gastrointestinal adverse effects. The results of our meta-analysis also suggested that 
the 12-month DAPT may be a reasonable compromise rather than the optimal duration. 
DAPT duration should be individualized for each patient after considering the thrombotic and 
bleeding risk. Duration of less than 12 months after DES implantation may be more widely 
offered, especially for those at high bleeding risks. Extended duration may be an option for 
low bleeding risk population.  
Our meta-analysis was not without limitations. Inevitably, there were differences among the 
trials with regard to patient characteristics and definitions of primary endpoints and major 
bleeding [30]. Patients in the trials and their outcomes may not be representative of 
real-world patients because of better compliance and follow-up, and exclusions of high-risk 
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patients. ARCTIC-Interruption, DES-LATE and DAPT excluded patients with major 
bleeding in the first year therapy. Different P2Y12 antagonists (clopidogrel, prasugrel, and 
ticagrelor) and different types of DES were used across and within clinical trials; all of these 
may differ in the benefit-risk ratio in the setting of DAPT after DES. There is scope for more 
clinical studies comparing different stents and different DAPT drug regimens. The relatively 
low heterogeneity across trials in the pooled analysis and consistent results in the sensitivity 
analyses suggested that our conclusions were robust. Nevertheless, the availability of 
patient-level data would allow a variety of subgroup analyses and add further insights.  
5 Conclusions 
This meta-analysis demonstrates the potential benefits in extending DAPT beyond 12 months 
in reducing the risk of myocardial infarction and stent thrombosis after DES implantation. 
However, there is a substantial increase in the risk of all-cause mortality and major bleeding. 
Short-term DAPT less than 12 months decreases the incidence of major bleeding without 
apparent alteration in other primary outcomes. Continuing DAPT beyond 12 months can be 
considered after a careful consideration of the risks and benefits in selected patients with low 
bleeding risk and very high ischemic risk. Physicians have to explain the increased risk of 
major bleeding to patients and take measures to minimize the risk. The increase in the rate of 
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all-cause mortality but not cardiovascular mortality resulted from extended DAPT requires 
further investigation.  
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The following are the supplementary data related to this article. 
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Multimedia Component 1 
Supplementary Table S1. Summary for blinding, randomization and placebo control of studies 
Study Blinding Randomization assignment Presence of Placebo Time of randomization 
ARCTIC-Interruption Open-labelled 
Assignments were made by using an interactive voice 
response system with a 1:1 ratio stratified by study site. 
No placebo control 
1 year after DES 
implantation 
DAPT Double-blinded 
Assignments were made with a computer-generated 
randomization schedule and stratified according to the type 
of stent received (DES vs. BMS), hospital site, study sites. 
With placebo control 
12 months after DES 
implantation 
DES-LATE Open-labelled 
Assignments were made according to a pre-established, 
computer-generated randomization scheme on the basis of 
the site and the type of drug in the DES. 
No placebo control 
12-18 months after DES 
implantation 
EXCELLENT Open-labelled 
Randomization was performed with a Web-based response 
system and stratified by the study sites and lesion length. 
No placebo control Before DES implantation 
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ISAR-SAFE Double-blinded 
Randomization was conducted in a 1:1 ratio via sealed 
opaque envelopes containing a computer-generated 
sequence with randomly permuted block lengths. 
With placebo control 
6 months after DES 
implantation 
ITALIC Open-labelled 
Assignments were made by centralized randomization 
using an interactive web-based system into ratio of 1:1. 
No placebo control 
6 months after DES 
implantation 
OPTIDUAL Open-labelled 
Randomization was stratified with interactive voice 
response system. 
No placebo control 
At 12±3 months after DES 
implantation 
OPTIMIZE Open-labelled 
Randomization was conducted in a 1:1 ratio with the use of 
a block size of 8 and stratified by study sites. 
No placebo control Before DES implantation 
PRODIGY Open-labelled 
Both randomizations for received stent type and DAPT 
duration were performed with a computer-generated 
sequence produced in coordinating center with random 
No placebo control 
Stent randomization: 
before DES implantation; 
Randomization of DAPT 
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block size of 4, 8 and 12. duration: 30 ±5 days after 
DES implantation 
RESET Open-labelled 
Randomization was performed by using an interactive 
web-based response system into a 1:1 ratio and stratified 
by study sites and clinical or lesion characteristics. 
No placebo control Before DES implantation 
SECURITY Open-labelled 
Randomization was performed by electronic case report, 
according to a 1:1 scheme, balanced within the center by 
blocks of 4. 
No placebo control After DES implantation 
Abbreviations used in Supplementary Table S1: DAPT: Dual Anti-platelet therapy; DES: Drug-eluting stent; BMS: Bare-meta stent. 
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Supplementary Table S2. Risk of Bias Reporting 
Study 
Sequence 
generation 
Allocation 
concealment 
Blinding of participants 
and personnel 
Blinding of 
outcome 
Incomplete 
outcome data 
Free from 
other bias 
>12 months treatment vs. 12 months treatment 
ARCTIC-Interruption Low Low Unclear Low Low Low 
DES-LATE Low Low Unclear Low Low Low 
OPTIDUAL Low Low Unclear Low Low Low 
DAPT Low Low Low Low Low Low 
>12 months treatment vs. <12 months treatment 
PRODIGY Low Low Unclear Low Low Low 
12 months treatment vs. <12 months treatment 
EXCELLENT Low Low Unclear Low Low Low 
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RESET Low Low Unclear Low Low Low 
OPTIMIZE Low Unclear Unclear Low Low Low 
ISAR-SAFE Low Unclear Low Low Low Low 
ITALIC Low Low Low Low Low Low 
SECURITY Low Low Unclear Low Low Low 
Each domain of risk was assigned “Low” for low risk, “Unclear” for unclear risk and “High” for high risk. 
 
 
 
  
44 
 
Supplementary Table S3. Sensitivity analysis of the effect of prolonging the duration of dual antiplatelet therapy to more than 12 months on 
frequency of all-cause mortality in patients after drug-eluting stent implantation 
 
STUDY 
Before excluding study After excluding study 
OR p-value I2 Chi2 P-value OR p-value I2 Chi2 P-value 
ARCTIC-Interruption 1.43 0.04 65% 8.58 0.002 1.39 0.04 68% 6.35 0.006 
DAPT 1.43 0.04 65% 8.58 0.002 1.16 0.04 69% 6.40 0.46 
DES-LATE 1.43 0.04 65% 8.58 0.002 1.44 0.01 77% 8.59 0.006 
OPTIDUAL 1.43 0.04 65% 8.58 0.002 1.62 0.35 5% 2.11 0.0002 
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 Supplementary Table S4. Sensitivity analysis of the effect of prolonging the duration of dual antiplatelet therapy to more than 12 months on 
frequency of definite or probable stent thrombosis in patients after drug-eluting stent implantation  
 
STUDY 
Before excluding study After excluding study 
OR p-value I2 Chi2 P-value OR p-value I2 Chi2 P-value 
ARCTIC-Interruption 0.36 0.12 49% 5.88 <0.00001 0.37 0.06 63% 5.48 <0.00001 
DAPT 0.36 0.12 49% 5.88 <0.00001 0.67 0.25 28% 2.76 0.32 
DES-LATE 0.36 0.12 49% 5.88 <0.00001 0.32 0.12 53% 4.22 <0.00001 
OPTIDUAL 0.36 0.12 49% 5.88 <0.00001 0.33 0.30 18% 2.44 <0.00001 
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Supplementary Table S5. Analysis of funnel plots in supplementary figures 2 to 6 to assess publication bias 
Suppl. 
Figure 
Begg’s rank correlation test Egger’s regression intercept Trim and fill 
Before trimming After trimming 
τ without continuity 
correction 
p-value p-value 
Observed Point 
estimate (LL-UL) 
Trimming 
direction 
Adjusted Point estimate (LL-UL) 
S2A 0.667 0.174 0.029 0.563 (0.432-0.734) Left 0.508 (0.380-0.679) 
S2B 0.143 0.652 0.924 0.886 (0.693-1.132) Not Applicable 0.886 (0.693-1.132) 
S3A 0.333 0.497 0.480 0.464 (0.196-1.098) Left 0.353 (0.135-0.925) 
S3B -0.238 0.453 0.291 0.833 (0.531-1.306) Not Applicable 0.833 (0.531-1.306) 
S4A -0.333 0.602 0.925 1.027 (0.720-1.464) Right 1.105 (0.791-1.546) 
S4B -0.200 0.624 0.460 0.986 (0.716-1.358) Right 1.015 (0.742-1.388) 
S5A 0.667 0.174 0.499 0.930 (0.670-1.292) Not Applicable 0.930 (0.670-1.292) 
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S5B 0.048 0.881 0.958 1.135 (0.733-1.756) Not Applicable 1.135 (0.733-1.756) 
S6A 0.000 1.000 0.996 1.324 (0.792-2.215) Left 1.219 (0.716-2.075) 
S6B 0.428 0.176 0.159 1.076 (0.851-1.360) Left 1.056 (0.838-1.330) 
S7A 0.000 1.000 0.786 1.503 (1.121-2.015) Not Applicable 1.503 (1.121-2.015) 
S7B 0.429 0.176 0.204 1.919 (1.213-3.037) Left 1.778 (1.150-2.752) 
S8A -0.333 0.602 0.334 1.134 (0.872-1.474) Right 1.246 (0.996-1.558) 
S8B 0.000 1.000 0.957 0.874 (0.713-1.071) Not Applicable 0.874 (0.713-1.071) 
Abbreviations used in Supplementary Table S5: LL: Lower limit; Suppl. Figure: Supplementary Figure; UL: Upper limit 
 
 
 
 
 
 
 
 
 
48 
 
